300705 九典制药
已收盘 08-23 15:00:00
资讯
新帖
简况
九典制药获华福证券买入评级,业绩超预期,在研管线丰富
金融界 · 27分钟前
九典制药获华福证券买入评级,业绩超预期,在研管线丰富
华福证券:给予九典制药买入评级
证券之星 · 56分钟前
华福证券:给予九典制药买入评级
九典制药(300705)2024年中报简析:营收净利润同比双双增长
证券之星 · 06:12
九典制药(300705)2024年中报简析:营收净利润同比双双增长
九典制药获开源证券买入评级,高基数下继续快速增长
金融界 · 08-24 22:12
九典制药获开源证券买入评级,高基数下继续快速增长
开源证券:给予九典制药买入评级
证券之星 · 08-24 22:06
开源证券:给予九典制药买入评级
九典制药(300705)6月30日股东户数0.95万户,较上期增加33.09%
证券之星 · 08-24 17:04
九典制药(300705)6月30日股东户数0.95万户,较上期增加33.09%
九典制药(300705.SZ)发布上半年业绩,净利润2.84亿元,同比增长43.77%
智通财经网 · 08-23 21:02
九典制药(300705.SZ)发布上半年业绩,净利润2.84亿元,同比增长43.77%
九典制药(300705)8月22日主力资金净卖出988.75万元
证券之星 · 08-22 15:19
九典制药(300705)8月22日主力资金净卖出988.75万元
九典制药新提交14件商标注册申请
证券之星 · 08-17
九典制药新提交14件商标注册申请
九典制药(300705.SZ)监事段斌、梁胜华拟合计减持不超19.37万股
智通财经 · 08-15
九典制药(300705.SZ)监事段斌、梁胜华拟合计减持不超19.37万股
九典制药最新公告:盐酸氨溴索口服溶液获得药品注册证书
证券之星 · 08-13
九典制药最新公告:盐酸氨溴索口服溶液获得药品注册证书
九典制药(300705.SZ):盐酸氨溴索口服溶液获药品注册证书
智通财经 · 08-13
九典制药(300705.SZ):盐酸氨溴索口服溶液获药品注册证书
多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等
中国制药网 · 08-12
多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等
九典制药最新公告:撤回药品注册申请
证券之星 · 08-11
九典制药最新公告:撤回药品注册申请
九典制药(300705)8月9日主力资金净卖出536.57万元
证券之星 · 08-09
九典制药(300705)8月9日主力资金净卖出536.57万元
九典制药(300705)8月6日主力资金净买入468.66万元
证券之星 · 08-06
九典制药(300705)8月6日主力资金净买入468.66万元
九典制药(300705)8月5日主力资金净买入165.64万元
证券之星 · 08-05
九典制药(300705)8月5日主力资金净买入165.64万元
九典制药获得外观设计专利授权:“保健食品包装盒(氨糖软骨素加钙片)”
证券之星 · 08-03
九典制药获得外观设计专利授权:“保健食品包装盒(氨糖软骨素加钙片)”
7月31日九典制药涨6.22%,安信医药健康股票A基金重仓该股
证券之星 · 07-31
7月31日九典制药涨6.22%,安信医药健康股票A基金重仓该股
九典制药涨6.22%,首创证券二个月前给出“买入”评级
证券之星 · 07-31
九典制药涨6.22%,首创证券二个月前给出“买入”评级
公司概况
公司名称:
湖南九典制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-10
主营业务:
湖南九典制药股份有限公司主营业务为医药产品的研发、生产和销售,产品主要包括药品制剂、原料药、药用辅料及CXO服务四大类别。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院,其被认定为湖南省企业技术中心,公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。
发行价格:
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":22.2,"timestamp":1724396604000,"preClose":22.48,"halted":0,"volume":3233695,"delay":0,"floatShares":294000000,"shares":487000000,"eps":0.8572,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.28,"latestTime":"08-23 15:00:00","open":22.45,"high":22.65,"low":21.91,"amount":71753600,"amplitude":0.0329,"askPrice":22.2,"askSize":46,"bidPrice":22.17,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.8572,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":22.48,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":24.73,"lowLimit":20.23,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":486526829,"pbRate":5.41,"roa":"--","roe":"6.17%","epsLYR":1.07,"committee":-0.243655,"marketValue":10801000000,"floatMarketCap":6531000000,"peRate":25.898273,"changeRate":-0.0125,"turnoverRate":0.011,"status":1},"requestUrl":"/m/hq/s/300705/wiki","defaultTab":"wiki","newsList":[{"id":"2462434156","title":"九典制药获华福证券买入评级,业绩超预期,在研管线丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2462434156","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462434156?lang=zh_cn&edition=full","pubTime":"2024-08-25 13:44","pubTimestamp":1724564659,"startTime":"0","endTime":"0","summary":"8月25日,九典制药获华福证券买入评级,近一个月九典制药获得3份研报关注。研报预计公司2024年上半年收入13.7亿,同比增长12.2%,归母净利润2.8亿,同比增长43.8%,扣非的归母净利润2.6亿, ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240825/c661108111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["161027","300705"],"gpt_icon":0},{"id":"2462648115","title":"华福证券:给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2462648115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462648115?lang=zh_cn&edition=full","pubTime":"2024-08-25 13:15","pubTimestamp":1724562915,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对九典制药进行研究并发布了研究报告《业绩超预期,在研管线丰富,长期成长动力充沛》,本报告对九典制药给出买入评级,当前股价为22.2元。 控费效果显著,销售费用率下降明显 公司持续加强对终端渠道掌控能力,持续降低销售费用。24H1公 司销售费用率为40%,同比下降8.7pct。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家;过去90天内机构目标均价为30.35。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500001916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","161027"],"gpt_icon":0},{"id":"2462693739","title":"九典制药(300705)2024年中报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2462693739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462693739?lang=zh_cn&edition=full","pubTime":"2024-08-25 06:12","pubTimestamp":1724537572,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期九典制药发布2024年中报。根据财报显示,九典制药营收净利润同比双双增长。截至本报告期末,公司营业总收入13.66亿元,同比上升12.19%,归母净利润2.84亿元,同比上升43.77%。其中,毛利率73.14%,同比减5.91%,净利率20.8%,同比增28.15%,销售费用、管理费用、财务费用总计5.95亿元,三费占营收比43.54%,同比减16.79%,每股净资产4.31元,同比减12.78%,每股经营性现金流0.86元,同比增49.89%,每股收益0.59元,同比增43.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"gpt_icon":0},{"id":"2461653457","title":"九典制药获开源证券买入评级,高基数下继续快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2461653457","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461653457?lang=zh_cn&edition=full","pubTime":"2024-08-24 22:12","pubTimestamp":1724508778,"startTime":"0","endTime":"0","summary":"8月24日,九典制药获开源证券买入评级,近一个月九典制药获得2份研报关注。研究报告称,2024H1公司实现营业收入13.67亿元,同比增长12.19%;归母净利润2.84亿元,同比增长43.77%;扣非归母 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240824/c661106499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["161027","300705"],"gpt_icon":0},{"id":"2461653528","title":"开源证券:给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461653528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461653528?lang=zh_cn&edition=full","pubTime":"2024-08-24 22:06","pubTimestamp":1724508380,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意近期对九典制药进行研究并发布了研究报告《公司信息更新报告:高基数下继续快速增长,利润率持续提升》,本报告对九典制药给出买入评级,当前股价为22.2元。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家;过去90天内机构目标均价为30.35。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400010310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300705"],"gpt_icon":0},{"id":"2461682265","title":"九典制药(300705)6月30日股东户数0.95万户,较上期增加33.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461682265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461682265?lang=zh_cn&edition=full","pubTime":"2024-08-24 17:04","pubTimestamp":1724490291,"startTime":"0","endTime":"0","summary":"证券之星消息,近日九典制药披露,截至2024年6月30日公司股东户数为9481.0户,较3月31日增加2357.0户,增幅为33.09%。在化学制药行业个股中,九典制药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2024年3月31日至2024年6月30日,九典制药区间涨幅为0.62%,在此期间股东户数增加2357.0户,增幅为33.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400009759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2461993315","title":"九典制药(300705.SZ)发布上半年业绩,净利润2.84亿元,同比增长43.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461993315","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461993315?lang=zh_cn&edition=full","pubTime":"2024-08-23 21:02","pubTimestamp":1724418131,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九典制药 发布2024年半年度报告,公司营业收入13.66亿元,同比增长12.19%;归属于上市公司股东的净利润2.84亿元,同比增长43.77%;归属于上市公司股东的扣除非经常性损益的净利润2.55亿元,同比增长43.24%;基本每股收益0.59元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300705"],"gpt_icon":0},{"id":"2461363545","title":"九典制药(300705)8月22日主力资金净卖出988.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461363545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461363545?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:19","pubTimestamp":1724311155,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月22日收盘,九典制药报收于22.48元,上涨2.09%,换手率1.52%,成交量4.46万手,成交额9956.69万元。8月22日的资金流向数据方面,主力资金净流出988.75万元,占总成交额9.93%,游资资金净流入1138.99万元,占总成交额11.44%,散户资金净流出150.24万元,占总成交额1.51%。九典制药主营业务:医药产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200020689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2460920627","title":"九典制药新提交14件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2460920627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460920627?lang=zh_cn&edition=full","pubTime":"2024-08-17 13:13","pubTimestamp":1723871621,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日湖南九典制药股份有限公司新提交14件商标注册申请。商标申请详情如下:今年以来湖南九典制药股份有限公司新申请注册商标76件,截止目前公司共持有注册商标578件,另有186件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081700014377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2459440123","title":"九典制药(300705.SZ)监事段斌、梁胜华拟合计减持不超19.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459440123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459440123?lang=zh_cn&edition=full","pubTime":"2024-08-15 19:17","pubTimestamp":1723720634,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九典制药(300705.SZ)公告,公司监事段斌、监事梁胜华拟减持公司股份,合计拟减持不超19.37万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1164861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2459818920","title":"九典制药最新公告:盐酸氨溴索口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2459818920","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459818920?lang=zh_cn&edition=full","pubTime":"2024-08-13 18:00","pubTimestamp":1723543254,"startTime":"0","endTime":"0","summary":"九典制药公告,公司于近日收到国家药品监督管理局下发的《药品注册证书》,药品名称为盐酸氨溴索口服溶液。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300036023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2459192268","title":"九典制药(300705.SZ):盐酸氨溴索口服溶液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2459192268","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459192268?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:38","pubTimestamp":1723541909,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九典制药(300705.SZ)公告,公司近日收到国家药品监督管理局下发的《药品注册证书》,药品名称为:盐酸氨溴索口服溶液。盐酸氨溴索口服溶液能增加呼吸道黏膜浆液腺的分泌和减少粘液腺分泌,从而降低痰液粘度,同时促进肺表面活性物质的分泌,增加支气管纤毛运动使痰液易于咳出,适用于急、慢性支气管炎引起的痰液粘稠、咳痰困难。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2458647940","title":"多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2458647940","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458647940?lang=zh_cn&edition=full","pubTime":"2024-08-12 11:24","pubTimestamp":1723433040,"startTime":"0","endTime":"0","summary":"公司于2022年9月向国家药品监督管理局递交该产品的上市注册申请并获得受理。上述研发药品注册申请的主动撤回并终止对公司研发工作无重大影响,对公司2024年度经营业绩也不会产生重大影响。业内表示,药企撤回相关药品注册申请,是医药行业一种常见的现象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081211281495913831&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081211281495913831&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","300705","BK0132","BK0239","300194","688553","BK0028"],"gpt_icon":0},{"id":"2458661253","title":"九典制药最新公告:撤回药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2458661253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458661253?lang=zh_cn&edition=full","pubTime":"2024-08-11 16:30","pubTimestamp":1723365033,"startTime":"0","endTime":"0","summary":"九典制药公告,因椒七麝凝胶贴膏需进一步完善有关试验数据,公司于近日向国家药品监督管理局提交了撤回椒七麝凝胶贴膏药品注册申请报告。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081100001552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2458953295","title":"九典制药(300705)8月9日主力资金净卖出536.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458953295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458953295?lang=zh_cn&edition=full","pubTime":"2024-08-09 15:25","pubTimestamp":1723188329,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月9日收盘,九典制药报收于23.21元,下跌3.77%,换手率1.87%,成交量5.5万手,成交额1.3亿元。8月9日的资金流向数据方面,主力资金净流出536.57万元,占总成交额4.14%,游资资金净流入754.8万元,占总成交额5.83%,散户资金净流出218.23万元,占总成交额1.68%。九典制药主营业务:医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080900025850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2457032093","title":"九典制药(300705)8月6日主力资金净买入468.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457032093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457032093?lang=zh_cn&edition=full","pubTime":"2024-08-06 15:22","pubTimestamp":1722928972,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月6日收盘,九典制药报收于24.07元,上涨0.17%,换手率0.98%,成交量2.89万手,成交额6940.59万元。8月6日的资金流向数据方面,主力资金净流入468.66万元,占总成交额6.75%,游资资金净流入26.1万元,占总成交额0.38%,散户资金净流出494.76万元,占总成交额7.13%。九典制药主营业务:医药产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600025048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2457471101","title":"九典制药(300705)8月5日主力资金净买入165.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457471101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457471101?lang=zh_cn&edition=full","pubTime":"2024-08-05 15:21","pubTimestamp":1722842511,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月5日收盘,九典制药报收于24.03元,上涨0.92%,换手率2.04%,成交量6.01万手,成交额1.46亿元。8月5日的资金流向数据方面,主力资金净流入165.64万元,占总成交额1.14%,游资资金净流入12.76万元,占总成交额0.09%,散户资金净流出178.41万元,占总成交额1.22%。九典制药主营业务:医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080500013963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2456256671","title":"九典制药获得外观设计专利授权:“保健食品包装盒(氨糖软骨素加钙片)”","url":"https://stock-news.laohu8.com/highlight/detail?id=2456256671","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456256671?lang=zh_cn&edition=full","pubTime":"2024-08-03 02:20","pubTimestamp":1722622847,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示九典制药新获得一项外观设计专利授权,专利名为“保健食品包装盒”,专利申请号为CN202330751988.5,授权日为2024年8月2日。专利摘要:1.本外观设计产品的名称:保健食品包装盒。5 .请求保护的外观设计包含色彩。今年以来九典制药新获得专利授权9个,较去年同期增加了28.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080300001704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2455261906","title":"7月31日九典制药涨6.22%,安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455261906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455261906?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:49","pubTimestamp":1722415759,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日九典制药涨6.22%,收盘报24.42元,换手率3.03%,成交量8.92万手,成交额2.15亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共63家,其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为16.61亿元,最新净值0.8381,较上一交易日下跌0.69%,近一年下跌28.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2455285906","title":"九典制药涨6.22%,首创证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455285906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455285906?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:49","pubTimestamp":1722415753,"startTime":"0","endTime":"0","summary":"今日九典制药涨6.22%,收盘报24.42元。2024年5月15日,首创证券研究员王斌发布了对九典制药的研报《公司简评报告:外用制剂快速增长,盈利能力稳健提升》,该研报对九典制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为89.3%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的蔡明子。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601136","300705"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.1218},{"period":"3month","weight":-0.1253},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.5268},{"period":"ytd","weight":-0.0562}],"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","perCapita":"31031股","boardName":"医药制造业","registeredCapital":"48652万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 湖南九典制药股份有限公司主营业务为医药产品的研发、生产和销售,产品主要包括药品制剂、原料药、药用辅料及CXO服务四大类别。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院,其被认定为湖南省企业技术中心,公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。","serverTime":1724566264386,"listedPrice":10.37,"stockholders":"9481人(较上一季度增加33.09%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}